-
2
-
-
0033432718
-
Assessing health-related quality-of-life in individuals with haemophilia
-
Miners AH, Sabin CA, Tolley KH. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia 1999, 5:378-85.
-
(1999)
Haemophilia
, vol.5
, pp. 378-385
-
-
Miners, A.H.1
Sabin, C.A.2
Tolley, K.H.3
-
3
-
-
34547757915
-
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
-
Manco-Johnson MJ, Abshire TC, Shapiro AD. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-44.
-
(2007)
N Engl J Med
, vol.357
, pp. 535-544
-
-
Manco-Johnson, M.J.1
Abshire, T.C.2
Shapiro, A.D.3
-
4
-
-
73949143119
-
Cost of care of haemophilia with inhibitors
-
Oct 21 [Epub ahead of print]
-
Di MinnoMND, Di MinnoG, Di CapuaM, Cerbone AM, Coppola A. Cost of care of haemophilia with inhibitors. Haemophilia 2009, Oct 21 [Epub ahead of print]
-
(2009)
Haemophilia
-
-
Di, M.1
Di, M.2
Di, C.3
Cerbone, A.M.4
Coppola, A.5
-
5
-
-
33646147385
-
Strategies towards a longer acting factor VIII
-
Saenko EL, Pipe SW. Strategies towards a longer acting factor VIII. Haemophilia 2006, 12(Suppl. 3):42-51.
-
(2006)
Haemophilia
, vol.12
, Issue.SUPPL. 3
, pp. 42-51
-
-
Saenko, E.L.1
Pipe, S.W.2
-
6
-
-
73949083366
-
Peg-interferon in acute and chronic hepatitis C: a review
-
May 19 [Epub ahead of print]
-
Palumbo E. Peg-interferon in acute and chronic hepatitis C: a review. Am J Ther 2009, May 19 [Epub ahead of print]
-
(2009)
Am J Ther
-
-
Palumbo, E.1
-
7
-
-
34248658822
-
Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol
-
Takagi A, Yamashita N, Yoshioka T. Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol. J Control Release 2007, 119:271-8.
-
(2007)
J Control Release
, vol.119
, pp. 271-278
-
-
Takagi, A.1
Yamashita, N.2
Yoshioka, T.3
-
8
-
-
61549130569
-
Targeted drugs and nanomedicine: present and future
-
Debbage P. Targeted drugs and nanomedicine: present and future. Curr Pharm Des 2009, 15:153-72.
-
(2009)
Curr Pharm Des
, vol.15
, pp. 153-172
-
-
Debbage, P.1
-
9
-
-
1842735217
-
Formulation of liposomes associated with recombinant interleukin-2: effect on interleukin-2 activity
-
Pellequer Y, Ollivon M, Barratt G. Formulation of liposomes associated with recombinant interleukin-2: effect on interleukin-2 activity. Biomed Pharmacother 2004, 58:162-7.
-
(2004)
Biomed Pharmacother
, vol.58
, pp. 162-167
-
-
Pellequer, Y.1
Ollivon, M.2
Barratt, G.3
-
10
-
-
0033974941
-
Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes
-
Kedar E, Gur H, Babai I. Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes. J Immunother 2000, 23:131-45.
-
(2000)
J Immunother
, vol.23
, pp. 131-145
-
-
Kedar, E.1
Gur, H.2
Babai, I.3
-
11
-
-
42649088435
-
A perspective on liposomal amphotericin B (AmBisome)
-
Richardson M, de Pauw B. A perspective on liposomal amphotericin B (AmBisome). Clin Microbiol Infect 2008, 14(Suppl. 4):1-4.
-
(2008)
Clin Microbiol Infect
, vol.14
, Issue.SUPPL. 4
, pp. 1-4
-
-
Richardson, M.1
de Pauw, B.2
-
12
-
-
59049085704
-
Review: doxorubicin delivery systems based on chitosan for cancer therapy
-
Tan ML, Choong PF, Dass CR. Review: doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol 2009, 61:131-42.
-
(2009)
J Pharm Pharmacol
, vol.61
, pp. 131-142
-
-
Tan, M.L.1
Choong, P.F.2
Dass, C.R.3
-
13
-
-
0344420226
-
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates
-
Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003, 55:1261-77.
-
(2003)
Adv Drug Deliv Rev
, vol.55
, pp. 1261-1277
-
-
Caliceti, P.1
Veronese, F.M.2
-
14
-
-
0037768710
-
Polymer vesicles in vivo: correlations with PEG molecular weight
-
Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release 2003, 90:323-34.
-
(2003)
J Control Release
, vol.90
, pp. 323-334
-
-
Photos, P.J.1
Bacakova, L.2
Discher, B.3
Bates, F.S.4
Discher, D.E.5
-
15
-
-
41349087510
-
Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin
-
Soloman R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. Clin Lymphoma Myeloma 2008, 8:21-32.
-
(2008)
Clin Lymphoma Myeloma
, vol.8
, pp. 21-32
-
-
Soloman, R.1
Gabizon, A.A.2
-
16
-
-
58949099540
-
Novel therapies for cutaneous T-cell lymphomas
-
Horwitz SM. Novel therapies for cutaneous T-cell lymphomas. Clin Lymphoma Myeloma 2008, 8(Suppl. 5):S187-92.
-
(2008)
Clin Lymphoma Myeloma
, vol.8
, Issue.SUPPL. 5
-
-
Horwitz, S.M.1
-
17
-
-
20444503381
-
Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy
-
Baru M, Carmel-Goren L, Barenholz Y. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost 2005, 93:1061-8.
-
(2005)
Thromb Haemost
, vol.93
, pp. 1061-1068
-
-
Baru, M.1
Carmel-Goren, L.2
Barenholz, Y.3
-
18
-
-
38349083504
-
Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A
-
Powell JS, Nugent DJ, Harrison JA. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 2008, 6:277-83.
-
(2008)
J Thromb Haemost
, vol.6
, pp. 277-283
-
-
Powell, J.S.1
Nugent, D.J.2
Harrison, J.A.3
-
19
-
-
51349110498
-
Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A
-
Spira J, Plyushch OP, Andreeva TA, Khametova RN. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. Thromb Haemost 2008, 100:429-34.
-
(2008)
Thromb Haemost
, vol.100
, pp. 429-434
-
-
Spira, J.1
Plyushch, O.P.2
Andreeva, T.A.3
Khametova, R.N.4
-
20
-
-
70350500718
-
Enhanced efficacy of recombinant FVIII in non-covalent complex with PEGylated liposome in hemophilia A mice
-
Epub 2009 Aug 4
-
Pan J, Liu T, Kim JY. Enhanced efficacy of recombinant FVIII in non-covalent complex with PEGylated liposome in hemophilia A mice. Blood 2009, 114:2802-11. Epub 2009 Aug 4
-
(2009)
Blood
, vol.114
, pp. 2802-2811
-
-
Pan, J.1
Liu, T.2
Kim, J.Y.3
-
21
-
-
33845241302
-
Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes
-
Spira J, Plyushch OP, Andreeva TA, Andreev Y. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006, 108:3668-73.
-
(2006)
Blood
, vol.108
, pp. 3668-3673
-
-
Spira, J.1
Plyushch, O.P.2
Andreeva, T.A.3
Andreev, Y.4
-
22
-
-
0032496674
-
The complement system in liposome clearance: can complement deposition be inhibited?
-
Bradley AJ, Devine DV. The complement system in liposome clearance: can complement deposition be inhibited? Adv Drug Deliv Rev 1998, 32:19-29.
-
(1998)
Adv Drug Deliv Rev
, vol.32
, pp. 19-29
-
-
Bradley, A.J.1
Devine, D.V.2
-
23
-
-
28244466864
-
Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity
-
Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005, 216:106-21.
-
(2005)
Toxicology
, vol.216
, pp. 106-121
-
-
Szebeni, J.1
-
24
-
-
51249103798
-
Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A
-
Martinowitz U, Lalezari S, Luboshitz J, Lubetsky A, Spira J. Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A. Haemophilia 2008, 14:1122-4.
-
(2008)
Haemophilia
, vol.14
, pp. 1122-1124
-
-
Martinowitz, U.1
Lalezari, S.2
Luboshitz, J.3
Lubetsky, A.4
Spira, J.5
-
25
-
-
73949101435
-
Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia A
-
Available at: Accessed September 30, 2009
-
Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia A. http://clinicaltrials.gov/ct2/show/NCT00623727, Available at: Accessed September 30, 2009
-
-
-
-
26
-
-
2342666603
-
An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa
-
Gale AJ, Pellequer JL. An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost 2003, 1:1966-71.
-
(2003)
J Thromb Haemost
, vol.1
, pp. 1966-1971
-
-
Gale, A.J.1
Pellequer, J.L.2
|